Early Cholesterol Treatment After Heart Attack Boosts Survival

⁢ Updated ‍June ‍01, 2025

Administering a combination of statins ⁣and ezetimibe soon after a heart attack substantially improves a patientS prognosis, according to a new study. Researchers⁣ from Lund university in Sweden and Imperial College London suggest that early intervention with this cholesterol-lowering drug combination could⁢ prevent thousands of recurrent heart attacks over the next decade.

Cardiovascular disease remains the leading cause of death globally,with myocardial infarction,or heart attack,being the ⁣most frequent acute event. The risk⁣ of a subsequent heart attack is highest within the first year ‍due to increased sensitivity in blood vessels, which promotes blood clot formation. Lowering LDL,⁤ or “bad” cholesterol, helps stabilize thes vascular changes, reducing the risk of further cardiac events. Current guidelines recommend immediate treatment with high-potency statins post-heart ‍attack to ‍lower cholesterol.

However, many patients fail to reach target cholesterol levels with statins alone, ‍necessitating add-on ⁤treatments like ezetimibe. Margrét Leósdóttir, associate ‍professor at Lund University, ⁢noted that current⁣ guidelines often lead to delays in treatment escalation, making it ineffective. She argues that earlier combination therapy could prevent more heart attacks.

Professor Kausik Ray, from Imperial College London, emphasized the potential⁤ to ‍save lives and reduce⁤ heart attacks by combining two low-cost drugs. He pointed out that the current lack of combined treatment results in avoidable deaths and places unneeded burdens on healthcare systems. The study advocates‍ for changes in post-heart attack care pathways.

The ⁣international research team examined outcomes for heart attack patients receiving statins combined with ezetimibe within 12 weeks, statins with later ezetimibe addition (13 weeks to‍ 16 months), or statins alone.

Analyzing Swedish registry data from ⁤36,000 patients between 2015 and 2022,⁣ the researchers emulated a clinical trial using advanced statistical models. Results indicated ⁤that early combination treatment led to better prognoses and reduced risks⁤ of new cardiovascular events and death,provided cholesterol levels were lowered to target levels ⁣early.

Researchers estimate that widespread early ezetimibe treatment could prevent numerous heart attacks, strokes, and deaths annually. Thay project that early ‍ezetimibe for all patients could avert 133 heart attacks per 10,000 patients over three years.

Leósdóttir noted that‍ combination therapy is not always applied upfront due⁤ to guideline ⁣limitations and concerns about side effects.However, she stressed the benefits ⁢of early intervention, highlighting the low side effect profile and affordability of ezetimibe.

“By giving⁣ patients a combination treatment earlier, we could help to prevent many⁣ more heart⁢ attacks,” said Margrét Leósdóttir, associate professor at Lund University.

What’s next

Leósdóttir⁢ hopes the research will influence guideline changes. Her hospital ⁢in Sweden has already⁣ implemented‍ a treatment algorithm to ‍guide lipid-lowering prescriptions post-myocardial infarction, leading to earlier treatment goal achievement. Professor Ray added that a⁣ simple change in ‍treatment guidelines could significantly impact patients and reduce healthcare demands, noting the cost-effectiveness of ‍ezetimibe.